Categories
Specials
Brand: smithkline beecham
Product Code: 16930
Price: 132EGP
Ex Tax: 132EGP
Rate this product

Example

Returns

You can return the product within 14 days of purchase.

Returns

You can return the product within 14 days of purchase.

Custom block
QUIBRON T/SR 300 MG BRONCHODILATOR ( THEOPHYLLINE ANHYDROUS ) 100 SUSTAINED RELEASE DIVIDOSE TABLETS
 

QUIBRON-T/SR 300 MG (THEOPHYLLINE ANHYDROUS) – DIVIDOSE SUSTAINED-RELEASE TABLETS

Prescription medicine

Quibron-T/SR 300 mg contains Theophylline Anhydrous 300 mg, a bronchodilator belonging to the methylxanthine class of medicines.

It features a sustained-release Dividose formulation designed to provide prolonged theophylline release, helping relax bronchial smooth muscles, widen the airways, and improve airflow in patients with certain respiratory conditions.

Pack size: 100 tablets.

Composition

  • Active ingredient: Theophylline Anhydrous 300 mg.
  • Pharmaceutical class: Methylxanthine bronchodilator.
  • Dosage form: Dividose sustained-release oral tablets.
  • Pack size: 100 tablets.

Mechanism of Action

Theophylline works through several mechanisms:

  • Inhibits phosphodiesterase enzymes (mainly PDE III and PDE IV), helping relax bronchial smooth muscles.
  • Produces bronchodilation, facilitating airflow through the respiratory passages.
  • Helps suppress airway responses to certain stimuli.
  • Enhances the contractile strength of the diaphragm, supporting respiratory muscle function.

Indications

Quibron-T/SR may be prescribed for the management of:

  • Bronchial asthma: Long-term management of symptoms associated with reversible airway obstruction.
  • Chronic bronchitis: Relief of bronchospasm associated with chronic airway inflammation.
  • Pulmonary emphysema: Management of respiratory symptoms associated with airflow obstruction.
  • Other chronic obstructive respiratory conditions: When theophylline is considered appropriate by the treating physician.

Important: It is intended for maintenance treatment and is not suitable for immediate relief of an acute asthma attack.

Benefits / Therapeutic Effects

  • Helps relax bronchial smooth muscles and widen the airways.
  • Supports improved airflow and respiratory function.
  • Helps reduce symptoms associated with reversible bronchial obstruction.
  • Supports respiratory muscle function by enhancing diaphragmatic contractility.
  • Sustained-release formulation provides prolonged drug delivery.

Dosage & Administration

  • Adults: Dosage should be individualized according to body weight, clinical response, tolerability, and serum theophylline concentrations.
  • Treatment is generally initiated at a relatively low dose and gradually adjusted under medical supervision.
  • The sustained-release formulation may allow administration at approximately 12-hour intervals in many patients, depending on the prescribed regimen.
  • Take orally as directed by the physician.
  • Swallow tablets according to the product instructions; do not crush or chew sustained-release tablets.
  • The Dividose formulation is designed to allow dose adjustments through tablet division; divide only as instructed by the product leaflet or healthcare professional.

Important: A 300 mg tablet is not automatically intended to be taken twice daily. Theophylline has a narrow therapeutic index, making individualized dosing and blood-level monitoring essential.

Possible Side Effects

Commonly reported side effects include:

  • Nausea and vomiting.
  • Headache.
  • Insomnia and sleep disturbances.
  • Restlessness and nervousness.
  • Tremors.
  • Palpitations and increased heart rate.
  • Diarrhea.
  • Irritability.

Potential signs of theophylline toxicity:

  • Persistent or severe vomiting.
  • Significant cardiac arrhythmias.
  • Severe agitation or confusion.
  • Seizures.

These symptoms require prompt medical evaluation, particularly when toxicity is suspected.

Contraindications & Precautions

  • Hypersensitivity to theophylline or any of the product's ingredients.
  • Use with extreme caution in patients with:
    • Active peptic ulcer disease.
    • Seizure disorders or epilepsy.
    • Cardiac arrhythmias.
    • Liver impairment.
    • Congestive heart failure.
    • Hyperthyroidism.
  • Elderly patients may require lower doses and more frequent monitoring.
  • Smoking and smoking cessation can significantly alter theophylline blood concentrations.
  • Persistent fever and acute infections may reduce theophylline clearance and increase the risk of toxicity.
  • Pregnancy and breastfeeding require medical assessment before use.

Drug Interactions

Several medications can significantly affect theophylline blood concentrations.

Medications that may increase theophylline concentrations:

  • Cimetidine.
  • Erythromycin.
  • Clarithromycin.
  • Ciprofloxacin.
  • Allopurinol (particularly at higher doses).
  • Fluvoxamine.

Medications that may decrease theophylline concentrations:

  • Carbamazepine.
  • Rifampicin.
  • Aminoglutethimide.

Patients should inform their healthcare provider about all medications they are taking before starting treatment.

Monitoring

  • Monitor serum theophylline concentrations to ensure therapeutic effectiveness and minimize toxicity.
  • Monitor heart rate and cardiac rhythm when clinically indicated.
  • Assess for gastrointestinal and neurological adverse effects.
  • Reassess theophylline levels following dose adjustments, changes in smoking habits, persistent fever, or the introduction or discontinuation of interacting medications.

Storage

  • Store according to the manufacturer's recommended storage conditions.
  • Keep in a dry place, away from excessive heat and moisture.
  • Keep out of reach of children.

References

  1. Quibron-T/SR Official Prescribing Information: Product composition, mechanism of action, indications, contraindications, dosage, and safety information.
  2. U.S. National Library of Medicine – DailyMed: Theophylline Extended-Release Tablets, official drug labeling and pharmacological information.
  3. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention, 2026.
  4. U.S. Food and Drug Administration (FDA): Theophylline extended-release prescribing information and therapeutic drug monitoring recommendations.

Patient Disclaimer:

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Quibron-T/SR is a prescription medication and should only be used under medical supervision. Do not start, discontinue, or adjust the dose without consulting your healthcare professional. Theophylline has a narrow therapeutic index, and inappropriate dosing may lead to serious or potentially life-threatening toxicity.

Write a review

Your Name:


Your Review: (optional) Text is optional. Maximum 1,000 characters. Reviews are published automatically after validation.

Rating: Bad           Good

Enter the code in the box below: